PDF(Pubmed)
Abstract：
Kinesin family protein 2A (KIF2A) is a microtubule depolymerase that participates in the progression of various cancers; however, its clinical utility in endometrial carcinoma (EC) remains unclear. The aim of the present study was to assess KIF2A expression and its relationship with prognosis in patients with EC. Data from 230 patients with EC who underwent tumor resection were reviewed in the current, retrospective study. KIF2A expression was measured in 230 formalin-fixed paraffin-embedded (FFPE) specimens of tumor tissue and 50 FFPE specimens of non-tumor tissue using immunohistochemistry (IHC). KIF2A expression was elevated in EC tumor tissue vs. non-tumor tissue (P<0.001). Furthermore, tumor KIF2A expression was linked with lymphovascular invasion (P=0.004) and higher International Federation of Gynecology and Obstetrics (FIGO) stage (P=0.001). High tumor KIF2A expression (IHC score>3) was correlated with shorter disease-free survival (DFS; P=0.014) and overall survival (OS; P=0.012). Moreover, the time-dependent receiver operating characteristic curves revealed that tumor KIF2A expression had an acceptable use for estimating the relapse and death risks at each timepoint within 6 years, with each area under the curve remaining stable at ≥0.7. Notably, tumor KIF2A expression (high vs. low) independently forecast shorter DFS (hazard ratio, 2.506; P=0.013), but not OS (P>0.05). Furthermore, information from The Human Protein Atlas database indicated that high tumor KIF2A expression was associated with worse OS in patients with EC (P=0.027). Tumor KIF2A is not only associated with lymphovascular invasion and higher FIGO stage, but also reflects unfavorable survival in patients with EC.
摘要：
驱动蛋白家族蛋白2A（KIF2A）是一种微管解聚酶，参与各种癌症的进展；然而，其在子宫内膜癌（EC）中的临床应用尚不清楚。本研究的目的是评估KIF2A的表达及其与EC患者预后的关系。对230例接受肿瘤切除术的EC患者的数据进行了回顾，回顾性研究。使用免疫组织化学(IHC)在肿瘤组织的230份福尔马林固定石蜡包埋(FFPE)标本和非肿瘤组织的50份FFPE标本中测量KIF2A表达。KIF2A在EC肿瘤组织中表达升高与非肿瘤组织(P<0.001)。此外，肿瘤KIF2A表达与淋巴管浸润(P=0.004)和国际妇产科联合会(FIGO)分期(P=0.001)相关。高肿瘤KIF2A表达(IHC评分>3)与较短的无病生存期(DFS;P=0.014)和总生存期(OS;P=0.012)相关。此外，时间依赖性受试者工作特征曲线显示，肿瘤KIF2A表达在6年内每个时间点的复发和死亡风险评估中具有可接受的用途。曲线下的每个面积保持稳定在≥0.7。值得注意的是,肿瘤KIF2A表达（高vs.低)独立预测较短的DFS(危险比，2.506；P=0.013），而非OS(P>0.05)。此外，来自人类蛋白质图谱数据库的信息表明，高肿瘤KIF2A表达与EC患者的OS恶化相关（P=0.027）。肿瘤KIF2A不仅与淋巴管浸润和较高的FIGO分期有关，但也反映了EC患者的不良生存率。
